Epstein-Barr Virus (EBV)–Lymphoid Cell Interactions. I. Quantification of EBV Particles Required for the Membrane Immunofluorescence Assay and the Comparative Expression of EBV Receptors on Different Human B, T and Null Cell Lines
We report data on the number of Epstein-Barr virus (EBV) particles required to detect virus binding to target cells (Raji or BJA-B) by means of membrane immunofluorescence (MIF). After determining the optimum conditions for the MIF assay the following aspects of EBV—lymphoid cell interactions were examined: (i) binding of two different strains of EBV to various types of human lymphoid cell lines, (ii) expression of receptors for both EBV and complement on these lines and (iii) induction of EBV-induced nuclear antigen (EBNA) in the different target cells used. The results showed that a minimum of about 2.7 × 103 enveloped virus particles/cell were required for an optimum visualization of EBV binding to the target cells tested, and that a lymphoid cell may bear receptors for one prototype strain of EBV but not for the other. A number of cell lines, particularly those of T and null type which express EBV receptors, did not synthesize EBNA, thus indicating that these lines were resistant to EBV infection. Several of these lines, although expressing cell surface EBV receptors, lacked complement receptors.
AdamsR. A.,
PothierA.,
FlowersA.,
LazarusH.,
FarberS.,
FoleyG.1970; The question of Stemlines in human acute leukemia. Comparison of cells isolated in vitro and in vivo from a patient with acute lymphoblastic leukemia. Experimental Cell Research 62:5–10
AiutiF.,
CerottiniJ. C.,
CoombsR. R. A.1975; International Union of Immunological Societies (IUIS) Report, July 1974. Identification, enumeration and isolation of B and T lymphocytes from human peripheral blood. Clinical Immunology and Immunopathology 3:584–597
EinhornL.,
SteinitzM.,
YefenofE.,
ErnbergI.,
BakaksT.,
KleinG.1978; Epstein-Barr virus (EBV) receptors, complement receptors and EBV infectibility of different lymphocyte fractions of human peripheral blood. II. Epstein-Barr virus studies. Cellular Immunology 35:43–58
FoleyG. E.,
LazarusH.,
FarberS.,
UzmanB. G.,
BooneB. A.,
MaccartyR. E.1965; Continuous culture of human lymphoblasts from peripheral blood of a child with acute leukemia. Cancer 18:522–529
GlaserR.,
LenoirG.,
FerroneS.,
PellegrinoM. A.,
De ThéG.1977; Cell surface markers on epithelial-Burkitt hybrid cells superinfected with Epstein-Barr virus. Cancer Research 37:2291–2296
GreavesM. F.,
BrownG.,
RickinsonA. B.1975; Epstein-Barr virus binding sites on lymphocyte subpopulations and the origin of lymphoblasts in cultured lymphoid cell lines and in the blood of patients with infectious mononucleosis. Clinical Immunology and Immunopathology 3:514–524
HenleW.,
HenleG.1972; Epstein-Barr virus: the cause of infectious mononucleosis: a review. In Oncogenesis and Herpesviruses pp 187–209 Edited by
BiggsP. M.,
de TheG.,
PayneL. N.
Lyon: IARC Scientific Publications;
HinumaY.,
GraceJ. T.1967; Cloning of immunoglobulin-producing human leukemic and lymphoma cells in long term cultures. Proceedings of the Society for Experimental Biology and Medicine 124:107–111
HuangC. C.,
HouY.,
WoodsL. K.,
MooreG. E.,
MinowadaJ.1974; Genetic study of human lymphoid T-cell lines derived from lymphocytic leukemia. Journal of the National Cancer Institute 53:655–660
JondalM.,
KleinG.1973; Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes. Journal of Experimental Medicine 138:1365–1378
JondalM.,
KleinG.,
OldstoneM. B. A.,
BokishV.,
YefenofE.1976; Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scandinavian Journal of Immunology 5:401–410
KatsukiT.,
HinumaY.,
YamamotoN.,
AboT.,
KumagaiK.1977; Identification of the target cells in human B lymphocytes for transformation by Epstein-Barr virus. Virology 83:287–294
KleinG.,
LindahlT.,
JondalM.,
LeiboldW.,
MenezesJ.,
NilssonK.,
SundstrӧmC.1974; Continuous lymphoid cell lines with characteristics of B cells (bone-marrow-derived), lacking the Epstein-Barr virus genome and derived from three human lymphomas. Proceedings of the National Academy of Sciences of the United States of America 71:3283–3286
KleinG.,
ManneborgA.,
SteinitzM.1979; Differences in EBV receptor concentration between in vitro EBV-converted lymphoma sublines reflect biological differences between the converting viral substrains. International Journal of Cancer 23:197–200
MangiR. J.,
NiedermanJ. C.,
KelleheyJ. E.,
DwyerI. M.,
EvansA. S.,
KantorF. S.1974; Depression of cell-mediated immunity during acute infectious mononucleosis. New England Journal of Medicine 291:1149–1153
MenezesJ.,
LeiboldW.,
KleinG.1975a; Biological differences between Epstein-Barr virus strains with regard to lymphocyte transforming ability, superinfection and antigen induction. Experimental Cell Research 93:478–484
MenezesJ.,
LeiboldW.,
KleinG.,
ClementsG.1975b; Establishment and characterization of an Epstein-Barr virus (EBV) negative lymphoblastoid B cell line from an exceptional, EBV-genome negative African Burkitt’s lymphoma. Biomedicine 22:276–284
MenezesJ.,
JondalM.,
LeiboldW.,
DorvalG.1976; Epstein-Barr virus interactions with human lymphocyte subpopulations: virus adsorption, kinetics of expression of Epstein-Barr virus associated nuclear antigen, and lymphocyte transformation. Infection and Immunity 13:303–310
MenezesJ.,
SeigneurinJ. M.,
PatelP.,
BourkasA.,
LenoirG.1977; Presence of Epstein-Barr virus receptors, but absence of virus penetration in cells of an Epstein-Barr virus genome-negative human lymphoblastoid T line (Molt-4). Journal of Virology 22:816–821
MenezesJ.,
PatelP.,
BourkasA. E.1978a; Interaction of Epstein-Barr virus (EBV) with EBV-genome-negative, receptor-positive human lymphoid cell lines (LCL) derived from acute lymphoblastic leukemia (ALL) and lymphoma patients. In Advances in Comparative Leukemia Research 1977: pp 216–218 Edited by
BentvelzenP.,
HilgersJ.,
YohnD. S.
Amsterdam: Elsevier/North-Holland Biomedical Press;
MenezesJ.,
PatelP.,
DussaultM.,
BourkasA. E.1978b; Comparative studies on the induction of virus-associated nuclear antigen and early antigen by lymphocyte-transforming (B95-8) and nontransforming (P3HR-1) strains of Epstein-Barr virus. Intervirology 9:86–94
MinowadaJ.,
KleinG.,
CliffordP.,
KleinE.,
MooreG. E.1967; Studies of Burkitt lymphoma cells. I. Establishment of a cell line (B35M) and its characteristics. Cancer 20:1430–1437
MinowadaJ.,
OhnumaT.,
MooreG. E.1972; Rosette forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus derived lymphocytes. Journal of the National Cancer Institute 49:891–895
MinowadaJ.,
JanossyG.,
GreavesM. F.,
TsubotaT.,
SrivastavaB. I. S.,
MorikawaS.,
TatsumiE.1978; Expression of an antigen associated with acute lymphoblastic leukemia in human leukemia-lymphoma cell lines. Journal of the National Cancer Institute 60:1269–1277
MiyoshiI.,
HirakiS.,
TsubotaT.,
KubonishiI.,
MatsudaY.,
NakayamaT.,
KishimotoH.,
KimuraI.,
MasujiH.1977; Human B cell, T cell and null cell leukaemic cell lines derived from acute lymphoblastic leukaemias. Nature, London 267:843–844
MonroeJ. M.,
BrandtP. M.1970; Rapid semiquantitative method for screening large numbers of virus samples by negative staining electron microscopy. Applied Microbiology 20:259–262
NilssonK.,
SundstrӧmC.1974; Establishment and characteristics of two unique cell lines from patients with lymphosarcoma. International Journal of Cancer 13:808–823
PatelP. C.,
MenezesJ.,
BourkasA.,
DorvalG.,
RivardG. E.,
BoulayG.,
StanleyP.,
JoncasJ. H.1978; Rosette formation by human lymphoid cells with monkey red blood cells. Annales d’Immunology 129c:449–462
RobbJ. A.,
MartinR. G.1972; Genetic analysis of simian virus 40. III. Characterization of a temperature-sensitive mutant blocked at an early stage of productive infection in monkey cells. Journal of Virology 9:956–968
RobinsonJ. E.,
AndimanW. A.,
HendersonE.,
MillerG.1977; Host-determined differences in expression of surface marker characteristics on human and simian lymphoblastoid cell lines transformed by Epstein-Barr virus. Proceedings of the National Academy of Sciences of the United States of America 74:749–753
RosenfeldC.,
GoutnerA.,
VenuatA. M.,
ChoquetC.,
PicoJ. L.,
DoreJ. F.,
LiabeufA.,
DurandyA.,
DesgrangesC.,
De ThéG.1977; An effective human leukemic cell line: Reh. European Journal of Cancer 13:377–379
SchwaberJ. F.,
KleinG.,
ErnbergI.,
RosenA.,
LazarusH.,
RosenF. S.1980; Deficiency of Epstein-Barr virus (EBV) receptors on B lymphocytes from certain patients with common varied agammaglobulinemia. Journal of Immunology 124:2191–2196
SeigneurinJ. M.,
VuillaumeM.,
LenoirG.,
De ThéG.1977; Replication of Epstein-Barr virus: ultrastructural and immunofluorescent studies of P3HR-l-superinfected Raji cells. Journal of Virology 24:836–845
TraulK.,
MayyasiS.1975; Large scale production of Epstein-Barr virus. In Epstein Barr Virus Production, Concentration and Purification IARC Internal Technical Report no. 75 003. pp 81–98 Proceedings of a workshop organized jointly by National Cancer Institute, Bethesda, Md., and IARC, Lyon; France:
YefenofE.,
KleinG.,
JondalM.,
OldstoneM. B. A.1976; Surface markers on human B and T lymphocytes. IX. Two color immunofluorescence studies on the association between EBV receptors and complement receptors on the surface of lymphoid cell lines. International Journal of Cancer 17:693–700
YefenofE.,
KleinG.,
KvaruunyK.1977; Relationship between complement activation, complement binding and EBV adsorption by human hematopoietic cell lines. Cellular Immunology 31:225–233
Epstein-Barr Virus (EBV)–Lymphoid Cell Interactions. I. Quantification of EBV Particles Required for the Membrane Immunofluorescence Assay and the Comparative Expression of EBV Receptors on Different Human B, T and Null Cell Lines